222 related articles for article (PubMed ID: 33339348)
1. Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies.
Chiricozzi A; Gisondi P; Bellinato F; Girolomoni G
Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33339348
[TBL] [Abstract][Full Text] [Related]
2. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.
Wine-Lee L; Keller SC; Wilck MB; Gluckman SJ; Van Voorhees AS
J Am Acad Dermatol; 2013 Dec; 69(6):1003-13. PubMed ID: 24075223
[TBL] [Abstract][Full Text] [Related]
3. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
4. Vaccinations in patients with immune-mediated inflammatory diseases.
Rahier JF; Moutschen M; Van Gompel A; Van Ranst M; Louis E; Segaert S; Masson P; De Keyser F
Rheumatology (Oxford); 2010 Oct; 49(10):1815-27. PubMed ID: 20591834
[TBL] [Abstract][Full Text] [Related]
5. Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.
Huber F; Ehrensperger B; Hatz C; Chappuis F; Bühler S; Eperon G
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 29394383
[TBL] [Abstract][Full Text] [Related]
6. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
7. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
8. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
9. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
10. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
[TBL] [Abstract][Full Text] [Related]
11. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
[TBL] [Abstract][Full Text] [Related]
12. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review.
Zweegers J; Otero ME; van den Reek JM; van Lümig PP; Driessen RJ; Kievit W; Seyger MM; van de Kerkhof PC; de Jong EM
Acta Derm Venereol; 2016 May; 96(4):453-8. PubMed ID: 26537336
[TBL] [Abstract][Full Text] [Related]
14. Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
Blauvelt A; Armstrong AW; Krueger GG
J Drugs Dermatol; 2015 Aug; 14(8):805-12. PubMed ID: 26267724
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.
Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P
J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416
[TBL] [Abstract][Full Text] [Related]
17. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.
Papp KA; Haraoui B; Kumar D; Marshall JK; Bissonnette R; Bitton A; Bressler B; Gooderham M; Ho V; Jamal S; Pope JE; Steinhart AH; Vinh DC; Wade J
J Cutan Med Surg; 2019; 23(1):50-74. PubMed ID: 30463418
[TBL] [Abstract][Full Text] [Related]
18. Review of safety and efficacy of approved systemic psoriasis therapies.
Kaushik SB; Lebwohl MG
Int J Dermatol; 2019 Jun; 58(6):649-658. PubMed ID: 30246393
[TBL] [Abstract][Full Text] [Related]
19. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
